Loading...
Found 49 Solid Tumors trials
A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A first-in-man Phase 1, non-randomized, multi-centre, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection and to establish the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection in patients with solid tumours with demonstrated tumour uptake of [111In]-FPI-1547. Includes a sub-study of FPI-1175 …
The primary purpose of this study is to assess the safety and tolerability of an Investigational drug in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
NP-G2-044 Monotherapy Primary Objectives The primary objectives for patients receiving NP-G2-044 monotherapy are the following: - To identify the recommended Phase 2 dose (RP2D) of continuously dosed NP-G2-044 monotherapy (Mono-RP2D) and characterize its safety; and - To assess preliminary signals of NP-G2-044 anti-tumor efficacy when administered as continuously dosed monotherapy. …
study of surufatinib in combination with tislelizumab will evaluate the safety, and tolerability in patients with advanced solid tumors.
The purpose of this research study is to: • Test how safe RP-6306 and gemcitabine are when given together at different doses and on different schedules • Test how well RP-6306 and gemcitabine work together to shrink cancer in the body RP-6306 is a PKMYT1 inhibitor that is designed to …
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an IV infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled in the …
The study will evaluate the safety profile of escalating doses of continuous daily oral ATRN-119 and to determine the maximum tolerated dose (MTD) and recommended dose. ATRN-119 is a drug that has been developed to treat cancers by taking advantage of genetic mutations found only in the tumor and not …
The research study is being conducted to test a new investigational imaging agent called 89Zr-Df-IAB22M2C with positron emission tomography/computed tomography (PET/CT) scans on subjects with cancer who plan to be treated as part of the clinical care. The imaging agent could help the doctor see where your CD8+ T cells …
This study tests the effects of an investigational product, CT-0508, and to see how safe CT-0508 is for patients with advanced cancer. One purpose of this study is to see if CT-0508 cells can be made and then safely given back to patients with HER2-positive cancers. A second purpose is …
This is a phase 1 study with Highly-selective RET inhibiter, Blu-667, in patients with Thyroid Cancer, Non-Small cell lung cancer and other advanced solid tumors. The study will be conducted at multiple centers in the United States and Europe. the purpose of this trial is to determine the maximum tolerated …
Please choose between Voice or SMS based delivery of verification code
or